Immediate Impact
2 from Science/Nature 54 standout
Citing Papers
Colorectal cancer
2024 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
Works of K. Shimada being referenced
Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
2017
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| K. Shimada | 112 | 158 | 121 | 25 | 341 | |
| Ai‐Min Xu | 105 | 93 | 68 | 19 | 325 | |
| Giovanna Fabbretti | 104 | 66 | 105 | 27 | 322 | |
| Manoj Shah | 72 | 157 | 108 | 28 | 329 | |
| Akira Gochi | 79 | 165 | 75 | 29 | 356 | |
| Yuko Takano | 91 | 125 | 52 | 32 | 386 | |
| Jun Yan | 55 | 105 | 95 | 21 | 383 | |
| Taek Chung | 164 | 104 | 70 | 25 | 339 | |
| Yong Zhang | 115 | 107 | 79 | 31 | 362 | |
| Hironori Betsunoh | 65 | 102 | 108 | 24 | 355 | |
| Takehiko Hatano | 80 | 129 | 68 | 25 | 399 |
All Works
Loading papers...